Chapter 15 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands
References (51)
- et al.
Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation
Regul. Pept.
(2000) - et al.
Cloning and characterization of the human V3 pituitary vasopressin receptor
FEBS Lett.
(1994) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
J. Psychiatr Res.
(1999)- et al.
Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage
Eur. J. Pharmacol.
(1999) - et al.
Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues
Life Sci.
(1992) - et al.
Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor
J. Biol. Chem.
(1994) - et al.
Recent advances in the discovery and development of vasopressin antagonists: Peptide and nonpeptide V-1a and V-2 receptor antagonists
Curr. Pharm. Des.
(1997) - et al.
Species heterogeneity and antidiuretic hormone antagonists: what are the predictors?
- et al.
Molecular pharmacology of AVP and OT receptors and therapeutic potential
Drug News Perspect.
(1999) - et al.
OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema
Acta Neurochir. Suppl. (Wien)
(1997)
Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions
Br. J. Obstet. Gynaecol.
Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea
Br. J. Obstet. Gynaecol.
Expression cloning of an AVP-activated, calcium-mobilizing receptor from rabbit kidney medulla
Am. J. Physiol.
VACM-1, a cullin gene family member, regulates cellular signaling
Am. J. Physiol. Cell Physiol.
Vascular responses to vasopressin antagonists in man and rat
Clin. Sci. (Colch.)
Characterization of potent new vasopressin analogs to study vasopressin V1b receptors
J. Pept. Sci.
Vasopressin receptor localization and neuronal responsiveness in the rat brain
Small molecule ligands for oxytocin and vasopressin receptors
Med. Res. Rev.
Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system
Clin. Chem.
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Nature
Alpha 2-adrenergic stimulation and vasopressin in congestive heart failure
J. Cardiovasc. Pharmacol.
Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla
Endocrinology
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon
Rheumatology
Expression of the genes encoding the vasopressinactivated calcium-mobilizing receptor and the dual angiotensin II/vasopressin receptor in the rat central nervous system
J. Neuroendocrinol.
Vasopressin receptors
Cited by (102)
Efficacy and safety of TS-121, a novel vasopressin V<inf>1B</inf> receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study
2020, Journal of Psychiatric ResearchCitation Excerpt :AVP concentrations in plasma (van Londen et al., 1997) and in the paraventricular nucleus of the hypothalamus in postmortem studies (Purba et al., 1996) are elevated in a subgroup of patients with MDD, compared to healthy controls, raising the hypothesis that excess AVP contributes to HPA axis dysfunction in depression. AVP exerts its effects through three vasopressin receptor subtypes (V1A, V1B and V2 receptors) and the oxytocin receptor (Serradeil-Le Gal et al., 2002a). Among them, the V1B receptor, which is abundantly expressed in the anterior pituitary, mediates the regulation of HPA axis activity by AVP (Saito et al., 1995).
Diabetes exacerbates brain pathology following a focal blast brain injury: New role of a multimodal drug cerebrolysin and nanomedicine
2020, Progress in Brain ResearchCitation Excerpt :A malfunction in the hormone itself or its receptor causes other pathologies such as nephrogenic diabetes insipidus (Babey et al., 2011; Robinson and Verbalis, 2003; Schoneberg et al., 1998). Three kinds of vasopressin hormone receptors V1a, V1b, and V2 present in the body (Serradeil-Le Gall et al., 2002) regulate water reabsorption in the distal nephron via activating water channel protein called aquaporins (Dibas et al., 1998). After ADH production in hypothalamic neurons of the supraoptic and paraventricular nuclei, the hormone transported and released into the bloodstream from the posterior pituitary gland (Brownstein et al., 1980; Landgraf and Ludwig, 1991).
Translational Medicine Strategies for Drug Development for Impulsive Aggression
2019, Handbook of Behavioral NeuroscienceCitation Excerpt :For example, certain allosteric modulators of GABAA receptors show a bidirectional relationship with GABA in which case these agents enhance aggression at low doses and reduce aggression at high doses. VASO exerts its physiological and behavioral effects by binding to specific G-protein-coupled receptors (GPCRs) in the central nervous system and certain peripheral tissues/sites (Ring, 2005; Serradeil-Le Gal et al., 2002). Three distinct AVP receptor subtypes have been identified --V1a, V1b, and V2.
Renal medulla
2016, Nephrologie et TherapeutiqueVasopressin, Diabetes Insipidus, and the Syndrome of Inappropriate Antidiuresis
2015, Endocrinology: Adult and Pediatric